Media coverage about INC Research (NASDAQ:SYNH) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. INC Research earned a coverage optimism score of 0.04 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.1318912175168 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have effected Accern’s analysis:
- Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against INC Research Holdings, Inc. (INCR) and Encourages Investors to Contact the Firm … (businesswire.com)
- Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Filed Against INC Research Holdings, Inc., now known as Syneos Health, Inc. On Behalf of Shareholders (finance.yahoo.com)
- INC Research (SYNH) and The Competition Head-To-Head Analysis (americanbankingnews.com)
- The Klein Law Firm Notifies Shareholders of a Class Action Filed on Behalf of Syneos Health, Inc. (formerly INC … – GlobeNewswire (press release) (globenewswire.com)
- See what the IHS Markit Score report has to say about Syneos Health Inc. (finance.yahoo.com)
SYNH has been the subject of a number of recent research reports. Zacks Investment Research lowered INC Research from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Credit Suisse Group initiated coverage on INC Research in a research note on Wednesday, October 11th. They issued an “outperform” rating and a $68.00 target price for the company. Jefferies Group restated a “buy” rating and issued a $55.00 target price on shares of INC Research in a research note on Friday, November 10th. TheStreet upgraded INC Research from a “c” rating to a “b-” rating in a research note on Monday, November 6th. Finally, KeyCorp restated a “market perform” rating and issued a $46.00 target price (down from $68.00) on shares of INC Research in a research note on Monday, November 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $50.78.
INC Research (NASDAQ:SYNH) last announced its quarterly earnings results on Thursday, November 9th. The company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.09). INC Research had a negative net margin of 4.29% and a positive return on equity of 14.42%. The company had revenue of $592.21 million during the quarter, compared to the consensus estimate of $604.95 million. During the same quarter last year, the company earned $0.64 earnings per share. The business’s revenue was up 128.2% on a year-over-year basis. equities research analysts forecast that INC Research will post 2.15 earnings per share for the current fiscal year.
INC Research Company Profile
Syneos Health, Inc, formerly INC Research Holdings, Inc, is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for INC Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research and related companies with MarketBeat.com's FREE daily email newsletter.